Hypocalcemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(21 intermediate revisions by 2 users not shown)
Line 7: Line 7:
__NOTOC__
__NOTOC__
{{Hypocalcemia}}
{{Hypocalcemia}}
{{CMG}}; {{AE}} {{VKG}}
{{CMG}}; {{AE}} {{MKK}}


==Overview==
==Overview==
[[Hypocalcemia]] may develop in disorders associated with insufficient [[parathyroid hormone]] or vitamin D production or resistance to hormonal activities. Perturbations of calcium homeostasis can be caused by environmental factors or occur as a result of genetic mutations in the calcium-sensing receptor (as in type 1 [[autosomal dominant hypocalcemia]]), G<sub>s</sub> α subunit (as in type 1A and 1B [[pseudohypoparathyroidism]]), vitamin D hydroxylase (as in type 1 vitamin D-dependent [[rickets]] , and calcitriol receptor (as in type 2 vitamin D-dependent [[rickets]]).
[[Hypocalcemia]] may develop in disorders associated with insufficient [[parathyroid hormone]] or [[vitamin D]] production or resistance to hormonal activities. Perturbations of calcium [[homeostasis]] can be caused by environmental factors or occur as a result of genetic [[Mutation|mutations]] in the [[calcium-sensing receptor]] (as in type 1 [[autosomal dominant hypocalcemia]]), G<sub>s</sub> α subunit (as in type 1A and 1B [[pseudohypoparathyroidism]]), [[vitamin D]] [[Hydroxylation|hydroxylase]] (as in type 1 vitamin D-dependent [[rickets]] , and [[calcitriol]] receptor (as in type 2 vitamin D-dependent [[rickets]]).


==Pathophysiology==
==Pathophysiology==


=== Physiology ===
=== Physiology ===
The normal physiology of [[Hypocalcemia]] can be understood as follows:<ref name="pmid22439169">{{cite journal |vauthors=Fong J, Khan A |title=Hypocalcemia: updates in diagnosis and management for primary care |journal=Can Fam Physician |volume=58 |issue=2 |pages=158–62 |date=February 2012 |pmid=22439169 |pmc=3279267 |doi= |url=}}</ref><ref name="pmid23148147">{{cite journal |vauthors=Carroll R, Matfin G |title=Endocrine and metabolic emergencies: hypocalcaemia |journal=Ther Adv Endocrinol Metab |volume=1 |issue=1 |pages=29–33 |date=February 2010 |pmid=23148147 |pmc=3474611 |doi=10.1177/2042018810366494 |url=}}</ref>
The normal physiology of [[Hypocalcemia]] can be understood as follows:<ref name="pmid22439169">{{cite journal |vauthors=Fong J, Khan A |title=Hypocalcemia: updates in diagnosis and management for primary care |journal=Can Fam Physician |volume=58 |issue=2 |pages=158–62 |date=February 2012 |pmid=22439169 |pmc=3279267 |doi= |url=}}</ref><ref name="pmid23148147">{{cite journal |vauthors=Carroll R, Matfin G |title=Endocrine and metabolic emergencies: hypocalcaemia |journal=Ther Adv Endocrinol Metab |volume=1 |issue=1 |pages=29–33 |date=February 2010 |pmid=23148147 |pmc=3474611 |doi=10.1177/2042018810366494 |url=}}</ref>
* The normal concentrations of calcium in the body is maintained within the narrow range and that is required for the minimal activity of the many extra- and intracellular processes calcium regulates. 
* The normal concentrations of [[calcium]] in the body is maintained within the narrow range and that is required for the optimal activity of the many extra- and intracellular processes that calcium regulates. 
* Calcium transport within the blood is mainly bound to plasma proteins like albumin (45%), phosphate and citrate(15%) and ionized state(40%).
* [[Calcium]] transport within the [[blood]] is mainly via bound to [[plasma proteins]] such as [[albumin]] (45%), [[phosphate]] and [[citrate]] (15%) and ionized state (40%).
* Only the ionized form of calcium is active but most laboratories show report of total serum calcium concentrations.
* Only the [[ionized]] form of calcium is active but most laboratories show report of total serum [[calcium]] concentrations.
* The normal concentration of calcium ranges between 8.5 and 10.5 mg/dL.
* The normal concentration of [[calcium]] ranges between 8.5 and 10.5 mg/dL.
* The normal range of ionized calcium in the plasma is 4.65 to 5.25 mg/dL.
* The normal range of [[ionized]] [[calcium]] in the plasma is 4.65 to 5.25 mg/dL.


=== Pathogenesis ===
=== Pathogenesis ===
It is understood that [[Hypocalcemia]] is the result caused by the following
It is understood that hypocalcemia may result through any of the following mechanisms:
 
==== Vitamin D deficiency ====
* One of the common causes of [[hypocalcemia]] is underproduction of [[vitamin D]].<ref name="pmid231481474">{{cite journal |vauthors=Carroll R, Matfin G |title=Endocrine and metabolic emergencies: hypocalcaemia |journal=Ther Adv Endocrinol Metab |volume=1 |issue=1 |pages=29–33 |date=February 2010 |pmid=23148147 |pmc=3474611 |doi=10.1177/2042018810366494 |url=}}</ref>
* The consequence of low serum calcium levels is an increase in [[serum]] [[Parathyroid hormone|PTH]] (to allow the calcium levels to return within normal range- mainly via increased release of [[calcium]] from [[bone]] [[Tissue (biology)|tissue]]).
* Causes of [[vitamin D]] deficiency include:<ref name="pmid3508718">{{cite journal |vauthors=Papapoulos SE, Harinck HI, Bijvoet OL, Gleed JH, Fraher LJ, O'Riordan JL |title=Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD |journal=Bone Miner |volume=1 |issue=1 |pages=69–78 |date=February 1986 |pmid=3508718 |doi= |url=}}</ref>
** Poor intake of [[vitamin D]]
** [[Malabsorption]]
** Reduced [[ultraviolet light]] exposure
** Decrease in 25-[[hydroxylation]] to convert vitamin D into 25-hydroxyvitamin D
** Decreased 1-[[hydroxylation]] of 25-hydroxyvitamin D (primarily occurrs in the [[kidney]]- so [[chronic kidney disease]] is one of the causes of reduced active form of [[vitamin D]] and hence hypocalcemia)


'''Hypoalbuminemia'''  
'''Hypoalbuminemia'''  
* When there is a fluctuation in the protein concentrations especially the one protein which is albumin,total calcium levels in the blood may change.<ref name="pmid224391692">{{cite journal |vauthors=Fong J, Khan A |title=Hypocalcemia: updates in diagnosis and management for primary care |journal=Can Fam Physician |volume=58 |issue=2 |pages=158–62 |date=February 2012 |pmid=22439169 |pmc=3279267 |doi= |url=}}</ref><ref name="pmid231481472">{{cite journal |vauthors=Carroll R, Matfin G |title=Endocrine and metabolic emergencies: hypocalcaemia |journal=Ther Adv Endocrinol Metab |volume=1 |issue=1 |pages=29–33 |date=February 2010 |pmid=23148147 |pmc=3474611 |doi=10.1177/2042018810366494 |url=}}</ref>
* When there is a fluctuation in serum [[protein]] concentrations, especially [[albumin]], total [[calcium]] levels in the [[blood]] may change.<ref name="pmid224391692">{{cite journal |vauthors=Fong J, Khan A |title=Hypocalcemia: updates in diagnosis and management for primary care |journal=Can Fam Physician |volume=58 |issue=2 |pages=158–62 |date=February 2012 |pmid=22439169 |pmc=3279267 |doi= |url=}}</ref><ref name="pmid231481472">{{cite journal |vauthors=Carroll R, Matfin G |title=Endocrine and metabolic emergencies: hypocalcaemia |journal=Ther Adv Endocrinol Metab |volume=1 |issue=1 |pages=29–33 |date=February 2010 |pmid=23148147 |pmc=3474611 |doi=10.1177/2042018810366494 |url=}}</ref>
* Whereas the levels of ionized calcium(free form) remains mostly constant, because it is hormonally regulated.
* Whereas the levels of [[ionized]] calcium (free form) remains mostly constant, because it is hormonally regulated.
* So that the total serum calcium levels may not accurately reflect the physiologically important ionized calcium concentration.
* In cases of hypoalbuminemia, total serum calcium levels may not accurately reflect the physiologically important ionized [[calcium]] concentration.
* Therefore, a correction may be required in order to arrive at the corrected calcium levels. (Corrected calcium = Measured calcium + 0.02 x  [40 - Albumin])


==== Hormone regulation  ====
==== Hormonal regulation  ====
* Parathyroid hormone (PTH) and vitamin D play a important role in regulating serum calcium.<ref name="pmid19923405">{{cite journal |vauthors=Riccardi D, Brown EM |title=Physiology and pathophysiology of the calcium-sensing receptor in the kidney |journal=Am. J. Physiol. Renal Physiol. |volume=298 |issue=3 |pages=F485–99 |date=March 2010 |pmid=19923405 |pmc=2838589 |doi=10.1152/ajprenal.00608.2009 |url=}}</ref>
* [[Parathyroid hormone]] (PTH) and [[vitamin D]] play an important role in regulating [[Calcium|serum calcium]].<ref name="pmid19923405">{{cite journal |vauthors=Riccardi D, Brown EM |title=Physiology and pathophysiology of the calcium-sensing receptor in the kidney |journal=Am. J. Physiol. Renal Physiol. |volume=298 |issue=3 |pages=F485–99 |date=March 2010 |pmid=19923405 |pmc=2838589 |doi=10.1152/ajprenal.00608.2009 |url=}}</ref>
* Calcium by itself controls to regulate its own serum levels via a calcium-sensing receptor (CaSR) in the parathyroid gland to inhibit parathyroid hormone (PTH) secretion and on a CaSR in the loop of Henle of the kidney to stimulate renal calcium excretion.<ref name="pmid14730506">{{cite journal |vauthors=Goodman WG |title=Calcium-sensing receptors |journal=Semin. Nephrol. |volume=24 |issue=1 |pages=17–24 |date=January 2004 |pmid=14730506 |doi= |url=}}</ref><ref name="pmid12815330">{{cite journal |vauthors=Quarles LD |title=Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues |journal=Curr. Opin. Nephrol. Hypertens. |volume=12 |issue=4 |pages=349–55 |date=July 2003 |pmid=12815330 |doi=10.1097/01.mnh.0000079682.89474.80 |url=}}</ref><ref name="pmid24992569">{{cite journal |vauthors=Toka HR, Pollak MR |title=The role of the calcium-sensing receptor in disorders of abnormal calcium handling and cardiovascular disease |journal=Curr. Opin. Nephrol. Hypertens. |volume=23 |issue=5 |pages=494–501 |date=September 2014 |pmid=24992569 |doi=10.1097/MNH.0000000000000042 |url=}}</ref><ref name="pmid18328986">{{cite journal |vauthors=Egbuna OI, Brown EM |title=Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations |journal=Best Pract Res Clin Rheumatol |volume=22 |issue=1 |pages=129–48 |date=March 2008 |pmid=18328986 |pmc=2364635 |doi=10.1016/j.berh.2007.11.006 |url=}}</ref>
* [[Calcium]] auto-regulates its own [[serum]] levels via a [[calcium-sensing receptor]] (CaSR) in the [[parathyroid gland]] to inhibit [[parathyroid hormone]] ([[Parathyroid hormone|PTH]]) secretion and on a CaSR in the loop of Henle of the [[kidney]] to stimulate [[renal]] [[calcium]] excretion.<ref name="pmid14730506">{{cite journal |vauthors=Goodman WG |title=Calcium-sensing receptors |journal=Semin. Nephrol. |volume=24 |issue=1 |pages=17–24 |date=January 2004 |pmid=14730506 |doi= |url=}}</ref><ref name="pmid12815330">{{cite journal |vauthors=Quarles LD |title=Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues |journal=Curr. Opin. Nephrol. Hypertens. |volume=12 |issue=4 |pages=349–55 |date=July 2003 |pmid=12815330 |doi=10.1097/01.mnh.0000079682.89474.80 |url=}}</ref><ref name="pmid24992569">{{cite journal |vauthors=Toka HR, Pollak MR |title=The role of the calcium-sensing receptor in disorders of abnormal calcium handling and cardiovascular disease |journal=Curr. Opin. Nephrol. Hypertens. |volume=23 |issue=5 |pages=494–501 |date=September 2014 |pmid=24992569 |doi=10.1097/MNH.0000000000000042 |url=}}</ref><ref name="pmid18328986">{{cite journal |vauthors=Egbuna OI, Brown EM |title=Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations |journal=Best Pract Res Clin Rheumatol |volume=22 |issue=1 |pages=129–48 |date=March 2008 |pmid=18328986 |pmc=2364635 |doi=10.1016/j.berh.2007.11.006 |url=}}</ref>
* Whenever the body serum ionized calcium goes down even in small amounts PTH (parathyroid hormone) is secreted instantaneously.And this occurs in 3 ways<ref name="pmid25287933">{{cite journal |vauthors=Blaine J, Chonchol M, Levi M |title=Renal control of calcium, phosphate, and magnesium homeostasis |journal=Clin J Am Soc Nephrol |volume=10 |issue=7 |pages=1257–72 |date=July 2015 |pmid=25287933 |pmc=4491294 |doi=10.2215/CJN.09750913 |url=}}</ref><ref name="pmid15891005">{{cite journal |vauthors=Akerström G, Hellman P, Hessman O, Segersten U, Westin G |title=Parathyroid glands in calcium regulation and human disease |journal=Ann. N. Y. Acad. Sci. |volume=1040 |issue= |pages=53–8 |date=April 2005 |pmid=15891005 |doi=10.1196/annals.1327.005 |url=}}</ref><ref name="pmid231481473">{{cite journal |vauthors=Carroll R, Matfin G |title=Endocrine and metabolic emergencies: hypocalcaemia |journal=Ther Adv Endocrinol Metab |volume=1 |issue=1 |pages=29–33 |date=February 2010 |pmid=23148147 |pmc=3474611 |doi=10.1177/2042018810366494 |url=}}</ref><ref name="pmid19396314">{{cite journal |vauthors=Carrillo-López N, Fernández-Martín JL, Cannata-Andía JB |title=[The role of calcium, calcitriol and their receptors in parathyroid regulation] |language=Spanish; Castilian |journal=Nefrologia |volume=29 |issue=2 |pages=103–8 |date=2009 |pmid=19396314 |doi=10.3265/Nefrologia.2009.29.2.5154.en.full |url=}}</ref>
* Whenever the [[serum]] ionized calcium decreases below normal (even in small amounts) [[PTH]] (parathyroid hormone) is secreted to aid in return of [[Calcium|serum calcium]] levels within normal range. This is achieved by 3 major actions of [[PTH]]: <ref name="pmid25287933">{{cite journal |vauthors=Blaine J, Chonchol M, Levi M |title=Renal control of calcium, phosphate, and magnesium homeostasis |journal=Clin J Am Soc Nephrol |volume=10 |issue=7 |pages=1257–72 |date=July 2015 |pmid=25287933 |pmc=4491294 |doi=10.2215/CJN.09750913 |url=}}</ref><ref name="pmid15891005">{{cite journal |vauthors=Akerström G, Hellman P, Hessman O, Segersten U, Westin G |title=Parathyroid glands in calcium regulation and human disease |journal=Ann. N. Y. Acad. Sci. |volume=1040 |issue= |pages=53–8 |date=April 2005 |pmid=15891005 |doi=10.1196/annals.1327.005 |url=}}</ref><ref name="pmid231481473">{{cite journal |vauthors=Carroll R, Matfin G |title=Endocrine and metabolic emergencies: hypocalcaemia |journal=Ther Adv Endocrinol Metab |volume=1 |issue=1 |pages=29–33 |date=February 2010 |pmid=23148147 |pmc=3474611 |doi=10.1177/2042018810366494 |url=}}</ref><ref name="pmid19396314">{{cite journal |vauthors=Carrillo-López N, Fernández-Martín JL, Cannata-Andía JB |title=[The role of calcium, calcitriol and their receptors in parathyroid regulation] |language=Spanish; Castilian |journal=Nefrologia |volume=29 |issue=2 |pages=103–8 |date=2009 |pmid=19396314 |doi=10.3265/Nefrologia.2009.29.2.5154.en.full |url=}}</ref>
** 1)PTH (parathyroid hormone) stimulation of calcium reabsorption in the distal tubule of the kidney results in decreased urinary calcium excretion by the kidney.<ref name="pmid8563701">{{cite journal |vauthors=Wu X, Sonnenberg H |title=Effect of renal perfusion pressure on excretion of calcium, magnesium, and phosphate in the rat |journal=Clin. Exp. Hypertens. |volume=17 |issue=8 |pages=1269–85 |date=November 1995 |pmid=8563701 |doi= |url=}}</ref>
** 1)[[Parathyroid hormone|PTH]] (parathyroid hormone) stimulation of [[calcium]] reabsorption in the [[Distal convoluted tubule|distal tubule of the kidney]] results in decreased [[urinary]] [[calcium]] excretion by the [[kidney]].<ref name="pmid8563701">{{cite journal |vauthors=Wu X, Sonnenberg H |title=Effect of renal perfusion pressure on excretion of calcium, magnesium, and phosphate in the rat |journal=Clin. Exp. Hypertens. |volume=17 |issue=8 |pages=1269–85 |date=November 1995 |pmid=8563701 |doi= |url=}}</ref>
** 2)PTH (parathyroid hormone) increases renal production of 1,25-dihydroxyvitamin D which is also called as calcitriol  which in turn increases the intestinal calcium absorption.<ref name="pmid9037127">{{cite journal |vauthors=Mortensen L, Hyldstrup L, Charles P |title=Effect of vitamin D treatment in hypoparathyroid patients: a study on calcium, phosphate and magnesium homeostasis |journal=Eur. J. Endocrinol. |volume=136 |issue=1 |pages=52–60 |date=January 1997 |pmid=9037127 |doi= |url=}}</ref>
** 2)[[PTH]] ([[parathyroid hormone]]) increases renal production of 1,25-dihydroxyvitamin D which is also called as calcitriol  which in turn increases the intestinal calcium absorption.<ref name="pmid9037127">{{cite journal |vauthors=Mortensen L, Hyldstrup L, Charles P |title=Effect of vitamin D treatment in hypoparathyroid patients: a study on calcium, phosphate and magnesium homeostasis |journal=Eur. J. Endocrinol. |volume=136 |issue=1 |pages=52–60 |date=January 1997 |pmid=9037127 |doi= |url=}}</ref>
** 3)PTH (parathyroid hormone) increases bone resorption which in turn increases the serum calcium levels.<ref name="PooleReeve2005">{{cite journal|last1=Poole|first1=K|last2=Reeve|first2=J|title=Parathyroid hormone — a bone anabolic and catabolic agent|journal=Current Opinion in Pharmacology|volume=5|issue=6|year=2005|pages=612–617|issn=14714892|doi=10.1016/j.coph.2005.07.004}}</ref>
** 3)[[PTH]] (parathyroid hormone) increases [[bone]] resorption which in turn increases the [[serum]] [[calcium]] levels.<ref name="PooleReeve2005">{{cite journal|last1=Poole|first1=K|last2=Reeve|first2=J|title=Parathyroid hormone — a bone anabolic and catabolic agent|journal=Current Opinion in Pharmacology|volume=5|issue=6|year=2005|pages=612–617|issn=14714892|doi=10.1016/j.coph.2005.07.004}}</ref>
* When PTH secretion is insufficient Hypokalemia may occur as the sequel, which is classically seen in hypoparathyroidism.
* When [[PTH]] secretion is insufficient [[hypokalemia]] may occur, which is classically seen in [[hypoparathyroidism]].
 
=== Magnesium  ===
* [[Hypocalcemia]] can be caused by both [[hypomagnesemia]] or by severe [[hypermagnesemia]].<ref name="pmid6709029">{{cite journal |vauthors=Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP |title=The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects |journal=N. Engl. J. Med. |volume=310 |issue=19 |pages=1221–5 |date=May 1984 |pmid=6709029 |doi=10.1056/NEJM198405103101904 |url=}}</ref><ref name="pmid18317951">{{cite journal |vauthors=van den Bergh WM, van de Water JM, Hoff RG, Algra A, Rinkel GJ |title=Calcium homeostasis during magnesium treatment in aneurysmal subarachnoid hemorrhage |journal=Neurocrit Care |volume=8 |issue=3 |pages=413–7 |date=2008 |pmid=18317951 |doi=10.1007/s12028-008-9068-9 |url=}}</ref>
* [[Magnesium]] depletion can lead to hypocalcemia by increasing [[parathyroid hormone]] (PTH) resistance.
* [[Parathyroid hormone]] ([[Parathyroid hormone|PTH]]) resistance occurs especially when [[serum]] [[magnesium]] concentrations fall below 0.8 mEq/L.
* In this patients hypocalcemia can be corrected by only correcting [[magnesium]] levels and by not giving calcium.
* Hypomagnesemia can be caused mostly by<ref name="pmid8859194">{{cite journal |vauthors=Kido Y, Okamura T, Tomikawa M, Yamamoto M, Shiraishi M, Okada Y, Kimura T, Sugimachi K |title=Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas |journal=Cancer |volume=78 |issue=8 |pages=1794–7 |date=October 1996 |pmid=8859194 |doi= |url=}}</ref><ref name="pmid88591942">{{cite journal |vauthors=Kido Y, Okamura T, Tomikawa M, Yamamoto M, Shiraishi M, Okada Y, Kimura T, Sugimachi K |title=Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas |journal=Cancer |volume=78 |issue=8 |pages=1794–7 |date=October 1996 |pmid=8859194 |doi= |url=}}</ref>
** [[Malabsorption]]
** Chronic [[alcoholism]]
** [[Cisplatin]] when combined with [[5-fluorouracil]] and [[leucovorin]]
** [[Diuretics]]
** [[Aminoglycosides]]


=== Acid-base disturbances ===
=== Acid-base disturbances ===


===='''Alkalosis'''====
===='''Alkalosis'''====
* In [[alkalosis]], [[hydrogen ion]]s dissociate from the negatively charged [[albumin]], which allows for increased calcium binding and leads to a decreased concentration of free calcium.
* In [[alkalosis]], [[hydrogen ion]]s dissociate from the negatively charged [[albumin]], which allows for increased calcium binding and leads to a decreased concentration of free [[calcium]].
 
* For an increase in pH of 0.1 unit, there is an approximately 0.05 mmol/L (0.1 mEq/L) fall in the serum level of ionized [[calcium]]. 


* For an increase in pH of 0.1 unit, there is an approximately 0.05 mmol/L (0.1 mEq/L) fall in the serum level of ionized calcium.
===='''Respiratory alkalosis'''====
* Reduced [[ionized]] [[calcium]] concentration and [[hypocapnia]] associated with [[hyperventilation]] may contribute to symptoms of [[vasoconstriction]] including [[lightheadedness]], [[fainting]], and [[paresthesia]].


===='''Respiratory Alkalosis'''====
===Globulin binding===
* Reduced ionized calcium concentration and [[hypocapnia]] associated with [[hyperventilation]] may contribute to symptoms of [[vasoconstriction]] including [[lightheadedness]], [[fainting]], and [[paresthesia]].
* [[Calcium]] binding to [[globulin]] is relatively small (1.0 g of [[globulin]] binds 0.2–0.3 mg of [[calcium]]) and generally does not influence the total [[serum]] [[calcium]] concentration.<ref>{{cite book | last = Taal | first = Maarten | title = Brenner & Rector's the kidney | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2012 | isbn = 978-1416061939 }}</ref>


===Globulin Binding===
=== Autoimmune ===
Calcium binding to [[globulin]] is relatively small (1.0 g of globulin binds 0.2–0.3 mg of calcium) and generally does not influence the total serum calcium concentration.<ref>{{cite book | last = Taal | first = Maarten | title = Brenner & Rector's the kidney | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2012 | isbn = 978-1416061939 }}</ref>
* [[Hypoparathyroidism]] which is [[acquired]] but not related to any [[surgery]] is most often an [[autoimmune disease]].<ref name="pmid3332555">{{cite journal |vauthors=Posillico JT, Wortsman J, Srikanta S, Eisenbarth GS, Mallette LE, Brown EM |title=Parathyroid cell surface autoantibodies that inhibit parathyroid hormone secretion from dispersed human parathyroid cells |journal=J. Bone Miner. Res. |volume=1 |issue=5 |pages=475–83 |date=October 1986 |pmid=3332555 |doi=10.1002/jbmr.5650010512 |url=}}</ref>  
* [[Autoimmune]] destruction of [[parathyroid glands]] results in permanent [[hypoparathyroidism]] .


== Genetics ==
== Genetics ==
The development of hypocalcemia is the result of genetic mutations such as
The development of [[hypocalcemia]] is the result of genetic [[Mutation|mutations]] such as
* Mutations in the transcription factor glial-cell missing B (GCMB).  
* [[Mutations]] in the [[Transcription (genetics)|transcription]] factor [[Glial cell|glial-cell]] missing B (GCMB).  
* Mutations in the calcium-sensing receptor, results in Autosomal dominant hypocalcemia (ADH).which is of 2 types<ref name="pmid8733126">{{cite journal |vauthors=Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB |title=Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism |journal=Hum. Mol. Genet. |volume=5 |issue=5 |pages=601–6 |date=May 1996 |pmid=8733126 |doi= |url=}}</ref><ref name="pmid11152759">{{cite journal |vauthors=Brown EM, MacLeod RJ |title=Extracellular calcium sensing and extracellular calcium signaling |journal=Physiol. Rev. |volume=81 |issue=1 |pages=239–297 |date=January 2001 |pmid=11152759 |doi=10.1152/physrev.2001.81.1.239 |url=}}</ref><ref name="pmid28176280">{{cite journal |vauthors=Szalat A, Shpitzen S, Tsur A, Zalmon Koren I, Shilo S, Tripto-Shkolnik L, Durst R, Leitersdorf E, Meiner V |title=Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia |journal=Endocrine |volume=55 |issue=3 |pages=741–747 |date=March 2017 |pmid=28176280 |doi=10.1007/s12020-017-1241-5 |url=}}</ref>
* Mutations in the [[calcium-sensing receptor]], results in [[autosomal dominant]] [[hypocalcemia]] (ADH).which is of 2 types<ref name="pmid8733126">{{cite journal |vauthors=Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB |title=Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism |journal=Hum. Mol. Genet. |volume=5 |issue=5 |pages=601–6 |date=May 1996 |pmid=8733126 |doi= |url=}}</ref><ref name="pmid11152759">{{cite journal |vauthors=Brown EM, MacLeod RJ |title=Extracellular calcium sensing and extracellular calcium signaling |journal=Physiol. Rev. |volume=81 |issue=1 |pages=239–297 |date=January 2001 |pmid=11152759 |doi=10.1152/physrev.2001.81.1.239 |url=}}</ref><ref name="pmid28176280">{{cite journal |vauthors=Szalat A, Shpitzen S, Tsur A, Zalmon Koren I, Shilo S, Tripto-Shkolnik L, Durst R, Leitersdorf E, Meiner V |title=Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia |journal=Endocrine |volume=55 |issue=3 |pages=741–747 |date=March 2017 |pmid=28176280 |doi=10.1007/s12020-017-1241-5 |url=}}</ref>
** Type 1: Autosomal dominant hypocalcemia (ADH) 1 is due to activating mutation in the CaSR.<ref name="pmid9253358">{{cite journal |vauthors=De Luca F, Ray K, Mancilla EE, Fan GF, Winer KK, Gore P, Spiegel AM, Baron J |title=Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=8 |pages=2710–5 |date=August 1997 |pmid=9253358 |doi=10.1210/jcem.82.8.4166 |url=}}</ref><ref name="pmid12915654">{{cite journal |vauthors=Hendy GN, Minutti C, Canaff L, Pidasheva S, Yang B, Nouhi Z, Zimmerman D, Wei C, Cole DE |title=Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=8 |pages=3674–81 |date=August 2003 |pmid=12915654 |doi=10.1210/jc.2003-030409 |url=}}</ref><ref name="pmid10770217">{{cite journal |vauthors=Lienhardt A, Garabédian M, Bai M, Sinding C, Zhang Z, Lagarde JP, Boulesteix J, Rigaud M, Brown EM, Kottler ML |title=A large homozygous or heterozygous in-frame deletion within the calcium-sensing receptor's carboxylterminal cytoplasmic tail that causes autosomal dominant hypocalcemia |journal=J. Clin. Endocrinol. Metab. |volume=85 |issue=4 |pages=1695–702 |date=April 2000 |pmid=10770217 |doi=10.1210/jcem.85.4.6570 |url=}}</ref><ref name="pmid8698326">{{cite journal |vauthors=Løvlie R, Eiken HG, Sørheim JI, Boman H |title=The Ca(2+)-sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism |journal=Hum. Genet. |volume=98 |issue=2 |pages=129–33 |date=August 1996 |pmid=8698326 |doi= |url=}}</ref>  
** Type 1: [[Autosomal dominant]] [[hypocalcemia]] (ADH) 1 is due to activating mutation in the CaSR.<ref name="pmid9253358">{{cite journal |vauthors=De Luca F, Ray K, Mancilla EE, Fan GF, Winer KK, Gore P, Spiegel AM, Baron J |title=Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=8 |pages=2710–5 |date=August 1997 |pmid=9253358 |doi=10.1210/jcem.82.8.4166 |url=}}</ref><ref name="pmid12915654">{{cite journal |vauthors=Hendy GN, Minutti C, Canaff L, Pidasheva S, Yang B, Nouhi Z, Zimmerman D, Wei C, Cole DE |title=Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=8 |pages=3674–81 |date=August 2003 |pmid=12915654 |doi=10.1210/jc.2003-030409 |url=}}</ref><ref name="pmid10770217">{{cite journal |vauthors=Lienhardt A, Garabédian M, Bai M, Sinding C, Zhang Z, Lagarde JP, Boulesteix J, Rigaud M, Brown EM, Kottler ML |title=A large homozygous or heterozygous in-frame deletion within the calcium-sensing receptor's carboxylterminal cytoplasmic tail that causes autosomal dominant hypocalcemia |journal=J. Clin. Endocrinol. Metab. |volume=85 |issue=4 |pages=1695–702 |date=April 2000 |pmid=10770217 |doi=10.1210/jcem.85.4.6570 |url=}}</ref><ref name="pmid8698326">{{cite journal |vauthors=Løvlie R, Eiken HG, Sørheim JI, Boman H |title=The Ca(2+)-sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism |journal=Hum. Genet. |volume=98 |issue=2 |pages=129–33 |date=August 1996 |pmid=8698326 |doi= |url=}}</ref>
** Type 2: Autosomal dominant hypocalcemia (ADH) 2 is due to activating mutation in the guanine nucleotide binding protein, alpha 11 gene(''GNA11)''.<ref name="pmid24823460">{{cite journal |vauthors=Li D, Opas EE, Tuluc F, Metzger DL, Hou C, Hakonarson H, Levine MA |title=Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization |journal=J. Clin. Endocrinol. Metab. |volume=99 |issue=9 |pages=E1774–83 |date=September 2014 |pmid=24823460 |pmc=4154081 |doi=10.1210/jc.2014-1029 |url=}}</ref><ref name="pmid23802516">{{cite journal |vauthors=Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H, Thakker RV |title=Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia |journal=N. Engl. J. Med. |volume=368 |issue=26 |pages=2476–2486 |date=June 2013 |pmid=23802516 |pmc=3773604 |doi=10.1056/NEJMoa1300253 |url=}}</ref>  
*** This [[mutation]] leads in shifting the set points of CaSR which results in no [[Parathyroid hormone|PTH]] release with altered changes in the levels of serum [[calcium]]. 
** Type 2: [[Autosomal dominant]] hypocalcemia ([[ADH]]) 2 is due to activating [[mutation]] in the [[guanine]] [[nucleotide]] binding [[protein]], alpha 11 [[gene]](''GNA11)''.<ref name="pmid24823460">{{cite journal |vauthors=Li D, Opas EE, Tuluc F, Metzger DL, Hou C, Hakonarson H, Levine MA |title=Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization |journal=J. Clin. Endocrinol. Metab. |volume=99 |issue=9 |pages=E1774–83 |date=September 2014 |pmid=24823460 |pmc=4154081 |doi=10.1210/jc.2014-1029 |url=}}</ref><ref name="pmid23802516">{{cite journal |vauthors=Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H, Thakker RV |title=Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia |journal=N. Engl. J. Med. |volume=368 |issue=26 |pages=2476–2486 |date=June 2013 |pmid=23802516 |pmc=3773604 |doi=10.1056/NEJMoa1300253 |url=}}</ref>
*** This [[mutation]] leads to [[Downstream (molecular biology)|downstream]] CaSR signaling.


==References==
==References==

Latest revision as of 11:34, 13 August 2018

https://https://www.youtube.com/watch?v=KWZrSYo7xuk%7C350}}

Hypocalcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypocalcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypocalcemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypocalcemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypocalcemia pathophysiology

CDC on Hypocalcemia pathophysiology

Hypocalcemia pathophysiology in the news

Blogs on Hypocalcemia pathophysiology

Directions to Hospitals Treating Hypocalcemia

Risk calculators and risk factors for Hypocalcemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Hypocalcemia may develop in disorders associated with insufficient parathyroid hormone or vitamin D production or resistance to hormonal activities. Perturbations of calcium homeostasis can be caused by environmental factors or occur as a result of genetic mutations in the calcium-sensing receptor (as in type 1 autosomal dominant hypocalcemia), Gs α subunit (as in type 1A and 1B pseudohypoparathyroidism), vitamin D hydroxylase (as in type 1 vitamin D-dependent rickets , and calcitriol receptor (as in type 2 vitamin D-dependent rickets).

Pathophysiology

Physiology

The normal physiology of Hypocalcemia can be understood as follows:[1][2]

  • The normal concentrations of calcium in the body is maintained within the narrow range and that is required for the optimal activity of the many extra- and intracellular processes that calcium regulates. 
  • Calcium transport within the blood is mainly via bound to plasma proteins such as albumin (45%), phosphate and citrate (15%) and ionized state (40%).
  • Only the ionized form of calcium is active but most laboratories show report of total serum calcium concentrations.
  • The normal concentration of calcium ranges between 8.5 and 10.5 mg/dL.
  • The normal range of ionized calcium in the plasma is 4.65 to 5.25 mg/dL.

Pathogenesis

It is understood that hypocalcemia may result through any of the following mechanisms:

Vitamin D deficiency

Hypoalbuminemia

  • When there is a fluctuation in serum protein concentrations, especially albumin, total calcium levels in the blood may change.[5][6]
  • Whereas the levels of ionized calcium (free form) remains mostly constant, because it is hormonally regulated.
  • In cases of hypoalbuminemia, total serum calcium levels may not accurately reflect the physiologically important ionized calcium concentration.
  • Therefore, a correction may be required in order to arrive at the corrected calcium levels. (Corrected calcium = Measured calcium + 0.02 x [40 - Albumin])

Hormonal regulation 

Magnesium 

Acid-base disturbances

Alkalosis

  • For an increase in pH of 0.1 unit, there is an approximately 0.05 mmol/L (0.1 mEq/L) fall in the serum level of ionized calcium.

Respiratory alkalosis

Globulin binding

Autoimmune 

Genetics

The development of hypocalcemia is the result of genetic mutations such as

References

  1. ↑ Fong J, Khan A (February 2012). "Hypocalcemia: updates in diagnosis and management for primary care". Can Fam Physician. 58 (2): 158–62. PMC 3279267. PMID 22439169.
  2. ↑ Carroll R, Matfin G (February 2010). "Endocrine and metabolic emergencies: hypocalcaemia". Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  3. ↑ Carroll R, Matfin G (February 2010). "Endocrine and metabolic emergencies: hypocalcaemia". Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  4. ↑ Papapoulos SE, Harinck HI, Bijvoet OL, Gleed JH, Fraher LJ, O'Riordan JL (February 1986). "Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD". Bone Miner. 1 (1): 69–78. PMID 3508718.
  5. ↑ Fong J, Khan A (February 2012). "Hypocalcemia: updates in diagnosis and management for primary care". Can Fam Physician. 58 (2): 158–62. PMC 3279267. PMID 22439169.
  6. ↑ Carroll R, Matfin G (February 2010). "Endocrine and metabolic emergencies: hypocalcaemia". Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  7. ↑ Riccardi D, Brown EM (March 2010). "Physiology and pathophysiology of the calcium-sensing receptor in the kidney". Am. J. Physiol. Renal Physiol. 298 (3): F485–99. doi:10.1152/ajprenal.00608.2009. PMC 2838589. PMID 19923405.
  8. ↑ Goodman WG (January 2004). "Calcium-sensing receptors". Semin. Nephrol. 24 (1): 17–24. PMID 14730506.
  9. ↑ Quarles LD (July 2003). "Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues". Curr. Opin. Nephrol. Hypertens. 12 (4): 349–55. doi:10.1097/01.mnh.0000079682.89474.80. PMID 12815330.
  10. ↑ Toka HR, Pollak MR (September 2014). "The role of the calcium-sensing receptor in disorders of abnormal calcium handling and cardiovascular disease". Curr. Opin. Nephrol. Hypertens. 23 (5): 494–501. doi:10.1097/MNH.0000000000000042. PMID 24992569.
  11. ↑ Egbuna OI, Brown EM (March 2008). "Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations". Best Pract Res Clin Rheumatol. 22 (1): 129–48. doi:10.1016/j.berh.2007.11.006. PMC 2364635. PMID 18328986.
  12. ↑ Blaine J, Chonchol M, Levi M (July 2015). "Renal control of calcium, phosphate, and magnesium homeostasis". Clin J Am Soc Nephrol. 10 (7): 1257–72. doi:10.2215/CJN.09750913. PMC 4491294. PMID 25287933.
  13. ↑ Akerström G, Hellman P, Hessman O, Segersten U, Westin G (April 2005). "Parathyroid glands in calcium regulation and human disease". Ann. N. Y. Acad. Sci. 1040: 53–8. doi:10.1196/annals.1327.005. PMID 15891005.
  14. ↑ Carroll R, Matfin G (February 2010). "Endocrine and metabolic emergencies: hypocalcaemia". Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  15. ↑ Carrillo-López N, Fernández-Martín JL, Cannata-Andía JB (2009). "[The role of calcium, calcitriol and their receptors in parathyroid regulation]". Nefrologia (in Spanish; Castilian). 29 (2): 103–8. doi:10.3265/Nefrologia.2009.29.2.5154.en.full. PMID 19396314.
  16. ↑ Wu X, Sonnenberg H (November 1995). "Effect of renal perfusion pressure on excretion of calcium, magnesium, and phosphate in the rat". Clin. Exp. Hypertens. 17 (8): 1269–85. PMID 8563701.
  17. ↑ Mortensen L, Hyldstrup L, Charles P (January 1997). "Effect of vitamin D treatment in hypoparathyroid patients: a study on calcium, phosphate and magnesium homeostasis". Eur. J. Endocrinol. 136 (1): 52–60. PMID 9037127.
  18. ↑ Poole, K; Reeve, J (2005). "Parathyroid hormone — a bone anabolic and catabolic agent". Current Opinion in Pharmacology. 5 (6): 612–617. doi:10.1016/j.coph.2005.07.004. ISSN 1471-4892.
  19. ↑ Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP (May 1984). "The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects". N. Engl. J. Med. 310 (19): 1221–5. doi:10.1056/NEJM198405103101904. PMID 6709029.
  20. ↑ van den Bergh WM, van de Water JM, Hoff RG, Algra A, Rinkel GJ (2008). "Calcium homeostasis during magnesium treatment in aneurysmal subarachnoid hemorrhage". Neurocrit Care. 8 (3): 413–7. doi:10.1007/s12028-008-9068-9. PMID 18317951.
  21. ↑ Kido Y, Okamura T, Tomikawa M, Yamamoto M, Shiraishi M, Okada Y, Kimura T, Sugimachi K (October 1996). "Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas". Cancer. 78 (8): 1794–7. PMID 8859194.
  22. ↑ Kido Y, Okamura T, Tomikawa M, Yamamoto M, Shiraishi M, Okada Y, Kimura T, Sugimachi K (October 1996). "Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas". Cancer. 78 (8): 1794–7. PMID 8859194.
  23. ↑ Taal, Maarten (2012). Brenner & Rector's the kidney. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1416061939.
  24. ↑ Posillico JT, Wortsman J, Srikanta S, Eisenbarth GS, Mallette LE, Brown EM (October 1986). "Parathyroid cell surface autoantibodies that inhibit parathyroid hormone secretion from dispersed human parathyroid cells". J. Bone Miner. Res. 1 (5): 475–83. doi:10.1002/jbmr.5650010512. PMID 3332555.
  25. ↑ Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB (May 1996). "Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism". Hum. Mol. Genet. 5 (5): 601–6. PMID 8733126.
  26. ↑ Brown EM, MacLeod RJ (January 2001). "Extracellular calcium sensing and extracellular calcium signaling". Physiol. Rev. 81 (1): 239–297. doi:10.1152/physrev.2001.81.1.239. PMID 11152759.
  27. ↑ Szalat A, Shpitzen S, Tsur A, Zalmon Koren I, Shilo S, Tripto-Shkolnik L, Durst R, Leitersdorf E, Meiner V (March 2017). "Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia". Endocrine. 55 (3): 741–747. doi:10.1007/s12020-017-1241-5. PMID 28176280.
  28. ↑ De Luca F, Ray K, Mancilla EE, Fan GF, Winer KK, Gore P, Spiegel AM, Baron J (August 1997). "Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor". J. Clin. Endocrinol. Metab. 82 (8): 2710–5. doi:10.1210/jcem.82.8.4166. PMID 9253358.
  29. ↑ Hendy GN, Minutti C, Canaff L, Pidasheva S, Yang B, Nouhi Z, Zimmerman D, Wei C, Cole DE (August 2003). "Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene". J. Clin. Endocrinol. Metab. 88 (8): 3674–81. doi:10.1210/jc.2003-030409. PMID 12915654.
  30. ↑ Lienhardt A, Garabédian M, Bai M, Sinding C, Zhang Z, Lagarde JP, Boulesteix J, Rigaud M, Brown EM, Kottler ML (April 2000). "A large homozygous or heterozygous in-frame deletion within the calcium-sensing receptor's carboxylterminal cytoplasmic tail that causes autosomal dominant hypocalcemia". J. Clin. Endocrinol. Metab. 85 (4): 1695–702. doi:10.1210/jcem.85.4.6570. PMID 10770217.
  31. ↑ Løvlie R, Eiken HG, Sørheim JI, Boman H (August 1996). "The Ca(2+)-sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism". Hum. Genet. 98 (2): 129–33. PMID 8698326.
  32. ↑ Li D, Opas EE, Tuluc F, Metzger DL, Hou C, Hakonarson H, Levine MA (September 2014). "Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization". J. Clin. Endocrinol. Metab. 99 (9): E1774–83. doi:10.1210/jc.2014-1029. PMC 4154081. PMID 24823460.
  33. ↑ Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H, Thakker RV (June 2013). "Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia". N. Engl. J. Med. 368 (26): 2476–2486. doi:10.1056/NEJMoa1300253. PMC 3773604. PMID 23802516.

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Hypocalcemia_pathophysiology&oldid=1489974"